Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) CFO Raphi Levy sold 2,871 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $43,065.00. Following the completion of the transaction, the chief financial officer owned 90,180 shares of the company’s stock, valued at approximately $1,352,700. The trade was a 3.09% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Raphi Levy also recently made the following trade(s):
- On Tuesday, August 11th, Raphi Levy sold 17,730 shares of Alpha Tau Medical stock. The shares were sold at an average price of $14.00, for a total transaction of $248,220.00.
- On Monday, July 6th, Raphi Levy sold 2,270 shares of Alpha Tau Medical stock. The stock was sold at an average price of $14.00, for a total transaction of $31,780.00.
- On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.00, for a total transaction of $232,349.00.
- On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total transaction of $27,693.54.
- On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $12.00, for a total value of $240,000.00.
- On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
- On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total value of $167,125.00.
- On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.
Alpha Tau Medical Price Performance
Shares of NASDAQ DRTS opened at $14.70 on Wednesday. The business has a 50-day moving average price of $12.64 and a 200 day moving average price of $9.73. The stock has a market cap of $1.33 billion, a PE ratio of -14.13 and a beta of 1.17. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. Alpha Tau Medical Ltd. has a 52-week low of $3.18 and a 52-week high of $15.02.
Hedge Funds Weigh In On Alpha Tau Medical
Hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in shares of Alpha Tau Medical during the first quarter worth about $286,000. Millennium Management LLC lifted its position in Alpha Tau Medical by 185.7% in the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after purchasing an additional 70,081 shares during the period. Mariner LLC lifted its position in Alpha Tau Medical by 1.6% in the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after purchasing an additional 1,915 shares during the period. Wells Fargo & Company MN boosted its holdings in Alpha Tau Medical by 291.7% in the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares in the last quarter. Finally, Everhart Financial Group Inc. purchased a new stake in Alpha Tau Medical in the 2nd quarter valued at approximately $126,000. 2.65% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the stock. Zacks Research raised shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. HC Wainwright raised their price objective on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. LADENBURG THALM/SH SH lifted their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Piper Sandler upped their target price on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a report on Tuesday, May 19th. Finally, Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Alpha Tau Medical currently has an average rating of “Moderate Buy” and an average price target of $12.80.
Check Out Our Latest Research Report on Alpha Tau Medical
About Alpha Tau Medical
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Read More
- Five stocks we like better than Alpha Tau Medical
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
